RxDoctor Payments Data

Roy Barco, MD

Internal Medicine · Muscle Shoals, ALNPI 1033436191

Payments from drug & device makers

$8,229in general payments, 2019–2025

Across 528 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$890
  • Lilly USA, LLC$770
  • AstraZeneca$389
  • Indivior Inc.$367
  • Pfizer$301
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$8,18699%
  • Education$431%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,229 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$308,476
Medicare patients
353
Services billed
9,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpclusaSofosbuvir/Velpatasvir12$295,550
MounjaroTirzepatide160$222,862
Prolastin CAlpha-1-Proteinase Inhibitor12$155,320
TrulicityDulaglutide84$138,231
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl535$118,161
EliquisApixaban100$76,873
FarxigaDapagliflozin Propanediol67$68,468
SuboxoneBuprenorphine Hcl/Naloxone Hcl99$68,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$59,934
JardianceEmpagliflozin53$50,803
LinzessLinaclotide63$39,595
JanuviaSitagliptin Phosphate42$38,886
OzempicSemaglutide30$36,120
VraylarCariprazine Hcl24$34,949
XareltoRivaroxaban23$29,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$770$361,093244 claims
GileadEpclusa$158$295,55012 claims
PfizerEliquis, Nurtec Odt, Premarin$301$90,835127 claims
GSKTrelegy Ellipta, Breo Ellipta$122$77,780101 claims
AbbVieLinzess, Vraylar$2,395$74,54487 claims
AstraZenecaFarxiga$389$68,46867 claims
Indivior Inc.Suboxone$367$68,07899 claims
Boehringer IngelheimJardiance, Tradjenta$54$64,40966 claims
Novo NordiskOzempic$292$36,12030 claims
Eisai Inc.Dayvigo$87$8,66817 claims
Antares Pharma, Inc.Xyosted$86$8,20414 claims
Scilex Pharmaceuticals Inc.Ztlido$248$4,70013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Muscle Shoals

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →